(Q47580213)

4 February 2018

title

Hepatitis C: the complications of immune dysfunction (English)

1 reference

4 February 2018

2

Christopher Trabue

1 reference

4 February 2018

author name string

Ellis King

1

1 reference

4 February 2018

Deling Yin

3

1 reference

4 February 2018

Zhi Q Yao

4

1 reference

4 February 2018

Jonathan P Moorman

5

1 reference

4 February 2018

publication date

1 March 2007

1 reference

4 February 2018

Expert Review of Clinical Immunology

published in

1 reference

4 February 2018

volume

3

1 reference

4 February 2018

issue

2

1 reference

4 February 2018

page(s)

145-157

1 reference

4 February 2018

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

cites work

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Hepatitis C: the clinical spectrum of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Hepatitis C in asymptomatic blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

The quasispecies of hepatitis C virus and the host immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Challenges in therapy of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Evidence for in vitro replication of hepatitis C virus genome in a human T-cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Presence of hepatitis C virus (HCV) RNA in the genital tracts of HCV/HIV-1-coinfected women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Anti B cell therapy (rituximab) in the treatment of autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Enhanced apoptosis of peripheral CD5-negative B lymphocytes from chronically hepatitis C virus-infected patients: reversal after antiviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Hepatitis C virus E2-CD81 interaction induces hypermutation of the immunoglobulin gene in B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Effect of hepatitis C virus core protein on the molecular profiling of human B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Interferon, PKR, virology, and genomics: what is past and what is next in the new millennium?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Hepatitis C virus: evasion of the interferon-induced antiviral response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Regulation of PKR and IRF-1 during hepatitis C virus RNA replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Natural T cell immunity to intracellular pathogens and nonpeptidic immunoregulatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Binding of the Hepatitis C Virus Envelope Protein E2 to CD81 Inhibits Natural Killer Cell Functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Inhibition of Natural Killer Cells through Engagement of CD81 by the Major Hepatitis C Virus Envelope Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Hepatitis C Virus Structural Proteins Impair Dendritic Cell Maturation and Inhibit In Vivo Induction of Cellular Immune Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Analysis of successful immune responses in persons infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Hepatitis C virus core protein: intriguing properties and functional relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

The HCV core protein acts as a positive regulator of fas-mediated apoptosis in a human lymphoblastoid T cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

The C-terminal region of hepatitis C core protein is required for Fas-ligand independent apoptosis in Jurkat cells by facilitating Fas oligomerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Hepatitis C virus core protein enhances FADD-mediated apoptosis and suppresses TRADD signaling of tumor necrosis factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Fcγ Receptor-like Activity of Hepatitis C Virus Core Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

An autoimmune domain-reduced HCV core gene remains effective in stimulating anti-core cytotoxic T lymphocyte activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Hepatitis C virus infection and type II cryoglobulinemia: an immunological perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Extrahepatic manifestations of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

A role for hepatitis C virus infection in type II cryoglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Effects of combined antiviral therapy on asymptomatic mixed cryoglobulinemia in naive patients with chronic hepatitis C virus infection: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Alcohol, smoking, and dietary status and susceptibility to malignant lymphoma in Japan: results of a hospital-based case-control study at Aichi Cancer Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Hepatitis C virus infection, mixed cryoglobulinemia, and B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Non-Hodgkin's lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Risk of non-Hodgkin's lymphoma in patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Prospective study of hepatitis C viral infection as a risk factor for subsequent B-cell neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Hepatitis C virus infection in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Hepatitis C virus, non-Hodgkin's lymphomas and hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Extrahepatic manifestations of HCV infection: facts and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

The origin of hepatitis C virus reinfecting transplanted livers: serum-derived versus peripheral blood mononuclear cell-derived virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Mixed IgG-IgM cryoglobulinemia with glomerulonephritis. Immunochemical, fluorescent and ultrastructural study of kidney and in vitro cryoprecipitate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Treatment of glomerulonephritides associated with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Interferon alpha and ribavirin for membranoproliferative glomerulonephritis and hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Peginterferon and dose-titrated ribavirin for hepatitis C-associated nephrotic membranoproliferative glomerulonephritis type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Accelerated decline of lung function in COPD patients with chronic hepatitis C virus infection: a preliminary study based on small numbers of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Accelerated decline in lung function and impaired reversibility with salbutamol in asthmatic patients with chronic hepatitis C virus infection: a 6-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Hepatitis C virus and the lung: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Induction of p38- and gC1qR-dependent IL-8 expression in pulmonary fibroblasts by soluble hepatitis C core protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Clinical manifestations of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Extrahepatic manifestations of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Immune-mediated complications during interferon therapy in hematological patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Extrahepatic immunological complications of hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Hepatitis C virus infection, cryoglobulinemia, and peripheral neuropathy: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Molecular analysis of VHI+ B lymphocytes in hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

Treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia—anti-viral therapy vs rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.3.2.145

21 January 2018

Identifiers

DOI

10.1586/1744666X.3.2.145

1 reference

4 February 2018

1 reference

4 February 2018